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Abstract Results obtained with PHAS-I proteins having Ser to
Ala mutations in the five known phosphorylation sites indicate
that mTOR preferentially phosphorylates Thr36 and Thr45. The
effects of phosphorylating these sites on eIF4E binding were
assessed in a far-Western analysis with a labeled eIF4E probe.
Phosphorylation of Thr36 only slightly attenuated binding of
PHAS-I to eIF4E, while phosphorylation of Thr45 markedly
inhibited binding. Phosphorylation of neither site affected the
electrophoretic mobility of the protein, indicating that results of
studies that rely solely on a gel-shift assay to assess changes in
PHAS-I phosphorylation must be interpreted with caution.
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1. Introduction
A key step in translation initiation is recognition of the
mRNA cap (m7GpppN, where N is any nucleotide), which
is located at the 5P-end of almost all eukaryotic mRNAs
[1,2]. The availability of the cap-binding protein, eIF4E, ap-
pears to control the rate of initiation, particularly of mRNAs
having structured 5P untranslated regions (UTRs) [3,4]. To
facilitate translation, eIF4E must interact with eIF4G, a large
sca¡olding protein that also binds eIF3 and eIF4A. eIF4A is
an ATP-dependent helicase, which melts secondary structure
allowing more e⁄cient translation of mRNAs with structured
5P UTRs. eIF3 links eIF4F to the 40S ribosomal subunit.
Access to eIF4E is controlled by a family of binding proteins
[5,6]. PHAS-I (also known as 4E-BP1) is the best character-
ized of these proteins. Non-phosphorylated PHAS-I binds
tightly to eIF4E and prevents eIF4E from binding to eIF4G
[7]. When phosphorylated in the appropriate site(s), PHAS-I
dissociates, allowing eIF4E to bind eIF4G to form eIF4F, the
complex of eIF4A, eIF4E, and eIF4G. eIF4F increases trans-
lation by increasing the e⁄ciency of binding and/or scanning
by the 40S ribosomal subunit.
Insulin and growth factors increase mRNA translation by
promoting the phosphorylation of PHAS-I [5,6]. In rat adipo-
cytes insulin promotes the phosphorylation of PHAS-I in ¢ve
S/T-P sites [8]. Several lines of evidence indicate that the ef-
fects of insulin are mediated in part by mTOR, a member of
the family of protein kinases having sequence homology to
phosphatidylinositol 3-kinase [9]. The e¡ects of insulin on in-
creasing the phosphorylation of PHAS-I are attenuated by
rapamycin [10,11], which is known to inhibit the function of
TOR proteins [9]. Expressing mTOR in cells mimics the e¡ect
of insulin by increasing phosphorylation of PHAS-I [12,13],
and mTOR is able to phosphorylate PHAS-I in vitro [12,14].
Recent ¢ndings suggests that Thr36 and Thr45 in PHAS-I are
preferentially phosphorylated by mTOR [14]. In the present
study, we have con¢rmed this site selectivity of mTOR and
have investigated the e¡ects of phosphorylating Thr36 and
Thr45 on the binding of PHAS-I to eIF4E.
2. Materials and methods
2.1. Preparation of recombinant PHAS-I proteins
cDNA encoding PHAS-I proteins having Ser/Thr to Ala mutations
in single sites were generated by oligonucleotide-directed mutagenesis
(Transformer Site-Directed Mutagenesis Kit, Clontech) using wild-
type PHAS-I cDNA in pBluescript SK3 (Stratagene) as template.
Sequential rounds of mutagenesis were used to generate a cDNA
encoding a PHAS-I having Ser/Thr to Ala mutations in all ¢ve known
Ser/Thr-Pro phosphorylation sites (Table 1). This cDNA was then
used as template to introduce mutations that restored Thr36, Thr45,
Ser64, Thr69, and Ser82, respectively. For each mutant plasmid, the
nucleotide sequence of the coding region was determined and found to
be free of undesired mutations. To express PHAS-I in bacteria, the
coding region was excised from pBluescript SK3 by using A£III and
BamHI, and inserted between NcoI and BamHI sites of pET-14b
(Novagen). Proper orientation and reading frame were veri¢ed by
nucleotide sequencing. PHAS-I proteins were puri¢ed by taking ad-
vantage of their binding to eIF4E by using essentially the same pro-
cedure as described previously for the puri¢cation of complexes of
histidine-tagged PHAS-I and eIF4E [11]. Samples of the puri¢ed com-
plexes were incubated at 100‡C for 5 min. This treatment is su⁄cient
to denature eIF4E, which was pelleted by centrifugation at 10 000Ug
for 30 min. PHAS-I proteins, which are heat-stable [15], were recov-
ered in the supernatants. The method allowed PHAS-I to be puri¢ed
without resorting to an epitope tag, which could change the properties
of this relatively small protein (MrW12 400). When subjected to SDS-
polyacrylamide gel electrophoresis, each mutant protein migrated pre-
dominantly as a single band of the same electrophoretic mobility as
wild-type PHAS-I. The PHAS protein concentration of each prepara-
tion was determined from the intensity of Coomassie blue staining
following SDS-PAGE. The preparations were devoid of eIF4E, as
assessed by Coomassie blue staining (a picture of a stained gel of
the protein preparations was provided during the review of the manu-
script).
All mutants reacted with an antibody [11] directed against the
COOH-terminal region of PHAS-I, indicating that the proteins were
translated in the correct reading frame. Moreover, all of the proteins
bound to eIF4E, both during puri¢cation and in far-Western analyses.
That the proteins retained high a⁄nity binding for eIF4E indicates
that the mutations did not perturb the intrinsic properties of the
PHAS-I proteins.
2.2. Phosphorylation of PHAS-I by mTOR
mTOR was immunoprecipitated from extracts of rat brain by using
the antibody, mTAb2, as described previously [16]. Immune com-
plexes were incubated at 30‡C for 30 min with 1 Wg of recombinant
PHAS-I protein in 50 Wl of reaction mixture containing 200 nM mi-
crocystin LR, 10 mM MnCl2, 50 mM NaCl, 0.1 mM EGTA, 1 mM
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dithiothreitol, 100 WM [Q-32P]ATP, and 10 mM NaHEPES, 50 mM
L-glycerophosphate, pH 7.4. The reactions were terminated by adding
5 Wl 0.2 M EDTA, before samples were subjected to SDS-PAGE.
2.3. Phosphorylation of PHAS-I by mitogen-activated protein (MAP)
kinase
Recombinant ERK2 isoform of MAP kinase was activated as de-
scribed previously [8]. When FLAG-4E binding was to be assessed,
PHAS-I proteins (20 Wg/ml) were incubated at 30‡C in a solution
containing activated MAP kinase (7 Wg/ml), 1 mM dithiothreitol,
0.5 mM ATP, 7.5 mM MgCl2 and 40 mM NaHEPES, pH 7.4 for
15 h. When phosphorylation stoichiometry was to be measured,
PHAS-I proteins were incubated under identical conditions except
in a reaction mixture containing 0.5 mM [Q-32P]ATP. The phospho-
rylation reactions were terminated by adding EDTA (20 mM ¢nal).
2.4. Electrophoretic analyses
Protein samples were subjected to electrophoresis in 15% polyacryl-
amide gels in the presence of SDS [17]. Dried gels were exposed to
¢lm to enable detection of 32P-labeled PHAS-I, and bands containing
the protein were excised. The amounts of 32P in the gel slices were
determined by measuring Cerenkov emissions. Binding of PHAS-I
proteins to eIF4E was assessed by far-Western blotting performed
using a 32P-labeled recombinant eIF4E fusion protein (FLAG-4E)
as described previously [18].
2.5. Peptide mapping
[32P]Phosphopeptides resulting from the sequential digestion of
PHAS-I proteins with lysyl endopeptidase C and chymotrypsin were
resolved by reverse phase HPLC as described previously [8].
3. Results
3.1. Phosphorylation of PHAS-I mutants by mTOR
Wild-type PHAS-I was phosphorylated by immune com-
plexes containing mTOR (Fig. 1). Almost no phosphorylation
was detected with immune complexes generated using non-
immune IgG instead of the mTOR antibody. mTOR intro-
duced very little phosphate into a 5A PHAS-I (Table 1), a
protein lacking the ¢ve known S/T-P sites that are phospho-
rylated in vivo [8]. To determine whether mTOR exhibited a
preference for any of the ¢ve sites, reactions were conducted
with mutant PHAS-I proteins that were generated by restor-
ing individual sites of phosphorylation into the 5A mutant.
mTOR readily phosphorylated T36 PHAS-I and T45 PHAS-I
under conditions in which S64 PHAS-I, T69 PHAS-I, and S82
PHAS-I were not signi¢cantly phosphorylated. These ¢ndings
Fig. 1. Phosphorylation of wild-type and mutant PHAS-I proteins
by mTOR. mTOR was immunoprecipitated from rat brain extracts
by using the antibody, mTAb2. Immune complexes generated with
non-immune IgG (NI-IgG) or with mTAb2 were incubated in 50 Wl
of reaction mixtures containing 0.5 Wg of the di¡erent PHAS-I pro-
teins. After 30 min the reactions were terminated, and samples were
subjected to SDS-PAGE. Pictures of autoradiograms of the dried
gels in the regions containing the PHAS-I proteins are presented.
Table 1
Designations of PHAS-I proteins used in this study
Designation Ser/Thr mutated to Ala
Wild-type PHAS-I None
T36 PHAS-I Thr45, Ser64, Thr69, Ser82
T45 PHAS-I Thr36, Ser64, Thr69, Ser82
S64 PHAS-I Thr36, Thr45, Thr69, Ser82
T69 PHAS-I Thr36, Thr45, Ser64, Ser82
S82 PHAS-I Thr36, Thr45, Ser64, Thr69
5A PHAS-I Thr36, Thr45, Ser64, Thr69, Ser82
Fig. 2. Phosphorylation of wild-type, T36, T45, and 5A PHAS-I by
MAP kinase. PHAS-I proteins were incubated with [Q-32P]ATP and
MAP kinase for 15 h before the reactions were terminated. Samples
were subjected to SDS-PAGE. An autoradiogram of the dried gel is
presented (A). To determine stoichiometry of phosphorylation,
PHAS-I proteins were incubated without and with MAP kinase as
described above, except that the reaction mixtures contained
[Q-32P]ATP. Samples were subjected to SDS-PAGE, and the bands
containing 32P-labeled PHAS-I proteins were excised. Phosphoryla-
tion stoichiometries were estimated from the amounts of 32P incor-
porated, which were determined by scintillation counting of gel sli-
ces containing the phosphorylated proteins (B). The results
presented are mean values þ S.E.M. from three experiments.
Fig. 3. Peptide mapping of PHAS-I proteins. Samples of 32P-labeled
wild-type PHAS-I (A), T36 PHAS-I (B) and T45 PHAS-I (C) that
had been phosphorylated by incubation with [Q-32P]ATP and MAP
kinase for 15 h were digested with lysyl endopeptidase before sam-
ples were subjected to reverse phase HPLC as described previously
[8]. More than 80% of the 32P from T36 PHAS-I and T45 PHAS-I
appeared in a single peak (LE-P3) (not shown), previously found to
contain Thr36 and Thr45 [8]. Fractions in LE-P3 were pooled and
the phosphopeptides were digested with chymotrypsin before sam-
ples were subjected to HPLC to resolve the peptides containing
Thr36 and Thr45 [8]. The results represent 32P (cpm) measured in
the eluate by using a £ow-through radiation monitor.
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support the conclusion that T36 and T45 are preferentially
phosphorylated by mTOR.
3.2. E¡ect of phosphorylating Thr36 and Thr45 on binding of
PHAS-I to eIF4E
To investigate the in£uence of Thr36 and Thr45 on eIF4E
binding, T36 PHAS-I and T45 PHAS-I were phosphorylated
in vitro with MAP kinase. We chose to use MAP kinase in-
stead of mTOR to phosphorylate PHAS-I in these experi-
ments because with the mTOR immune complexes we were
unable to con¢ne phosphorylation to Thr36 and Thr45 in the
relatively long incubations needed to approach stoichiometric
phosphorylation of these sites (data not shown). MAP kinase
phosphorylates PHAS-I in vitro in all ¢ve S/T-P sites that are
phosphorylated in response to insulin in adipocytes [8]. Thus,
MAP kinase is a useful tool for investigating the phospho-
rylation of PHAS-I in vitro, even if it does not phosphorylate
PHAS-I in cells [19] (discussed later). Moreover, recombinant
MAP kinase was available in a highly puri¢ed form, which
allowed us to conduct the phosphorylation reactions under
more precisely de¢ned conditions than were possible with
mTOR immunoprecipitated from cell extracts. Consequently,
the extent of phosphorylation from experiment to experiment
could be better controlled with recombinant MAP kinase.
T36 PHAS-I and T45 PHAS-I were incubated with MAP
kinase for 15 h to allow phosphorylation of Thr36 and Thr45
to approach completion. Under these conditions 5A PHAS-I
was not phosphorylated to a signi¢cant level (Fig. 2A), con-
sistent with the interpretation that all of the major MAP
kinase sites in PHAS-I have been identi¢ed. In contrast,
T36 PHAS-I and T45 PHAS-I were phosphorylated to nearly
1 mol/mol (Fig. 2B). Peptide mapping experiments were con-
ducted to con¢rm that Thr36 and Thr45 were phosphorylated
in the mutant proteins. The elution positions of phosphopep-
tides containing Thr36 and Thr45 derived from wild-type
PHAS-I are shown in Fig. 3A. The identities of the peptides
in the two peaks were determined previously by amino acid
sequencing [8]. T36 PHAS-I and T45 PHAS-I were phos-
phorylated almost exclusively in the peptides containing
Thr36 and Thr45, respectively (Fig. 3B,C).
To investigate the e¡ect of phosphorylation of Thr36 and
Thr45 on eIF4E binding, samples of wild-type and mutant
PHAS-I proteins that had been phosphorylated with unla-
beled ATP were subjected to far-Western analysis (Fig.
4A,B). As observed previously, phosphorylation of wild-type
PHAS-I abolished binding to eIF4E. Incubating 5A PHAS-I
with MAP kinase for 15 h did not decrease binding of the
mutant protein to 32P-labeled FLAG-4E (Fig. 4A,B). Phos-
phorylation of T36 PHAS-I caused a relatively small decrease
in binding to eIF4E, whereas phosphorylation decreased bind-
ing of T45 PHAS-I by 70%. Phosphorylation did not retard
the electrophoretic mobility of either mutant protein (Figs. 2A
and 4A).
4. Discussion
PHAS-I is phosphorylated in rat adipocytes in ¢ve sites, all
of which conform to a Ser/Thr-Pro motif [8]. Two of these
sites, Thr36 and Thr45, were preferentially phosphorylated in
vitro by mTOR that had been immunoprecipitated with the
non-activating antibody, mTAb2 (Fig. 1). These results are
consistent with the previous ¢ndings that Thr to Ala muta-
tions in these two sites essentially abolished phosphorylation
by an epitope-tagged mTOR that had been immunoprecipi-
tated with anti-myc antibody [14]. An extended incubation
with mTOR immunoprecipitated with the activating antibody,
mTAb1, resulted in the phosphorylation of all ¢ve S/T-P sites
in PHAS-I [16]. Although the Thr sites in PHAS-I were more
highly phosphorylated than the Ser sites in this study [16], the
preference of mTOR for Thr36 and Thr45 was less apparent
than in Fig. 1. This is partly explained by the high stoichiom-
etry of phosphorylation of PHAS-I previously achieved as a
result of using the activating antibody.
Results obtained with T45 PHAS-I indicate that phospho-
rylation of Thr45 is able to prevent PHAS-I from binding to
eIF4E (Fig. 4). As Thr45 is phosphorylated in a rapamycin-
sensitive manner in response to insulin [8], it seems reasonable
to conclude that this site is important in regulating binding to
eIF4E in cells. This conclusion is also supported by results of
previous studies that provided indirect evidence that Thr45
phosphorylation regulates eIF4E binding [8,14]. However, it
is important to remember that the conditions used to assess
binding in vitro di¡er from those in intact cells. Moreover,
while phosphorylation of Thr45 may be su⁄cient to block the
association of PHAS-I and eIF4E, it may not be su⁄cient to
promote dissociation of eIF4E, once the PHAS-I/eIF4E com-
plex has formed. Thus, phosphorylation of other sites in
PHAS-I as well as interactions with additional proteins may
be needed to promote the dissociation of PHAS-I and eIF4E
in cells.
The present results indicate that phosphorylation of Thr36
alone is not su⁄cient to block binding to eIF4E (Fig. 4).
Supporting this conclusion are previous ¢ndings that PHAS-
I phosphorylated in Thr36 remained bound to eIF4E in ex-
tracts of rat adipocytes [8]. Thr45 is located closer to the
Fig. 4. E¡ect on eIF4E binding of phosphorylating Thr36 or Thr45.
PHAS-I proteins were incubated in the absence (3) or presence (+)
of MAP kinase (MAPK) for 15 h before the reactions were termi-
nated. Samples were subjected to electrophoresis before proteins
were transferred to a membrane, which was incubated with a 32P-la-
beled FLAG-eIF4E probe (A). After washing the membrane, an
autoradiogram was prepared (FLAG-4E Binding). The membrane
was then stripped and reprobed with PHAS-I antibody to allow es-
timation of the relative amounts of PHAS-I (PHAS-I Blot) (A).
FLAG-4E binding is expressed as a percentage of the control bind-
ing, which is de¢ned as that observed with the respective samples
incubated in the absence of MAP kinase (B). The results represent
mean values þ S.E.M. from three experiments.
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eIF4E-binding domain [21] than Thr36, which may explain
the greater in£uence of Thr45 on eIF4E binding relative to
that of Thr36. Other issues remain to be resolved concerning
the role of Thr36 phosphorylation in the control of eIF4E
binding. The ¢nding that mutating Thr36 to Ala increased
the amount of eIF4E bound to PHAS-I expressed in
HEK293 cells led Burnette et al. [14] to conclude that phos-
phorylation of Thr36 modulates eIF4E binding. However,
these experiments did not assess directly the e¡ect of Thr36
phosphorylation on eIF4E binding. It is possible that phos-
phorylation of Thr36 facilitates phosphorylation of other sites
or acts in combination with the phosphorylation of other sites
to promote dissociation of PHAS-I and eIF4E. Indeed, we
stress that sites other than the two that are preferentially
phosphorylated by mTOR may contribute to the control of
eIF4E binding.
Ser64, which is the preferred site for phosphorylation by
MAP kinase in vitro, was the ¢rst in vivo phosphorylation
site in PHAS-I to be identi¢ed [23]. As phosphorylation of
Ser64 was markedly increased in response to insulin, which
promoted the dissociation of the PHAS-I/eIF4E complex, it
was suggested that phosphorylation of Ser64 was responsible
for the loss in eIF4E binding [18,20]. However, it was later
shown that Ser64 could be phosphorylated in vitro without
loss of eIF4E binding [8]. The possibility that Ser64 coopera-
tes with other sites to in£uence eIF4E binding has not been
eliminated. There is also reason to suspect that Thr69 has a
role in controlling eIF4E binding [8]. Unfortunately, we have
been unable to investigate directly the in£uence of Thr69
phosphorylation on eIF4E binding, as we have been unable
to phosphorylate Thr69 e⁄ciently in vitro.
The present ¢ndings have important implications with re-
spect to the relationship between electrophoretic mobility and
PHAS-I phosphorylation. The results indicate that phospho-
rylation of PHAS-I may occur without a change in electro-
phoretic mobility, provided phosphorylation is con¢ned to
Thr36 or Thr45 (Figs. 2A and 4A). Thus, the actual change
in phosphorylation of PHAS-I could be signi¢cantly under-
estimated from the change in mobility. In any event, it cannot
be concluded that the phosphorylation of PHAS-I does not
change because the electrophoretic mobility of the protein is
una¡ected by a treatment. In other experiments we have
found that phosphorylation of S82 PHAS-I, which was gen-
erated by restoring Ser82 in the 5A mutant, decreases its elec-
trophoretic mobility but does not signi¢cantly inhibit its bind-
ing to FLAG-4E (data not shown). The phosphorylation of
Ser82 provides a potential explanation for observations in cell
extracts of a form of PHAS-I of reduced electrophoretic mo-
bility that still binds to eIF4E (see [22], for example). The lack
of e¡ect of Ser82 phosphorylation on binding indicates that a
mobility shift does not necessarily re£ect phosphorylation of
sites that modulate eIF4E binding. It seems clear from these
considerations that studies of PHAS-I that rely solely on
changes in electrophoretic mobility to assess phosphorylation
of PHAS-I must be interpreted with caution.
PHAS-I is a substrate for MAP kinase in vitro [23]. How-
ever, it is not clear that PHAS-I serves as a substrate for MAP
kinase in vivo. Perhaps the strongest argument against a role
of MAP kinase was made by von Manteu¡el et al. [19], who
reported that MAP kinase could be activated in endothelial
cells without a¡ecting PHAS-I phosphorylation. This conclu-
sion may have been premature since PHAS-I phosphorylation
was assessed using a gel-shift assay. However, there is other
evidence that MAP kinase is not a PHAS-I kinase in cells and
the prevailing view is that PHAS-I is phosphorylated in cells
by an insulin-activated protein kinase other than MAP kinase
[24].
Identifying the protein kinases that phosphorylate PHAS-I
in cells is proving to be a di⁄cult task. Insulin appears to
utilize both rapamycin-sensitive and -insensitive pathways in
promoting the phosphorylation of PHAS-I [11,25]. mTOR is a
candidate for the kinase that mediates the rapamycin-sensitive
phosphorylation of Thr36 and Thr45 in PHAS-I. Additional
research is needed to determine the kinases involved in the
rapamycin-insensitive pathway, and the kinases that mediate
the phosphorylation of Ser64, Thr69, and Ser82.
References
[1] Hershey, J.W.B. (1991) Annu. Rev. Biochem. 60, 717^755.
[2] Merrick, W.C. (1992) Microbiol. Rev. 56, 291^315.
[3] Rhoads, R.E., Joshi, B. and Minich, W.B. (1994) Biochimie 76,
831^838.
[4] Sonenberg, N. (1994) Biochimie 76, 839^846.
[5] Lawrence Jr., J.C. and Abraham, R.T. (1997) Trends Biochem.
Sci. 22, 345^349.
[6] Sonenberg, N. and Gingras, A.-C. (1998) Curr. Opin. Cell Biol.
10, 268^275.
[7] Haghighat, A., Mader, S., Pause, A. and Sonenberg, N. (1995)
EMBO J. 14, 5701^5709.
[8] Fadden, P., Haystead, T.A.J. and Lawrence Jr., J.C. (1997)
J. Biol. Chem. 272, 10240^10247.
[9] Abraham, R.T. and Wiederrecht, G. (1996) Annu. Rev. Immu-
nol. 14, 483^510.
[10] Beretta, L., Gingras, A.-C., Svitkin, Y.V., Hall, M.N. and Sonen-
berg, N. (1996) EMBO J. 15, 658^664.
[11] Lin, T.-A., Kong, X., Saltiel, A.R., Blackshear, P.J. and Law-
rence Jr., J.C. (1995) J. Biol. Chem. 270, 18531^18538.
[12] Brunn, G.J., Hudson, C.C., Sekulic, A., Williams, J.M., Hosoi,
H., Houghton, P.J., Lawrence Jr., J.C. and Abraham, R.T.
(1997) Science 277, 99^101.
[13] Hara, K., Yonezawa, K., Kozlowski, M.T., Sugimoto, T., An-
drabi, K., Weng, Q.-P., Kasuga, M., Nishimoto, I. and Avruch,
J. (1997) J. Biol. Chem. 272, 26457^26463.
[14] Burnett, P.E., Barrow, R.K., Cohen, N.A., Snyder, S.H. and
Sabatini, D.M. (1998) Proc. Natl. Acad. Sci. USA 95, 1432^
1437.
[15] Hu, C., Pang, S., Kong, X., Velleca, M. and Lawrence Jr., J.C.
(1994) Proc. Natl. Acad. Sci. USA 91, 3730^3734.
[16] Brunn, G.J., Fadden, P., Haystead, T.A.J. and Lawrence Jr., J.C.
(1997) J. Biol. Chem. 272, 32547^32550.
[17] Laemmli, U.K. (1970) Nature 227, 680^685.
[18] Pause, A., Belsham, G.J., Gingras, A.-C., Donze, O., Lin, T.-A.,
Lawrence Jr., J.C. and Sonenberg, N. (1994) Nature 371, 762^
767.
[19] von Manteu¡el, S.R., Gingras, A.-C., Ming, X.-F., Sonenberg,
N. and Thomas, G. (1996) Proc. Natl. Acad. Sci. USA 93, 4076^
4080.
[20] Lin, T.-A., Kong, X., Pause, A., Haystead, T.A.J., Belsham, G.,
Sonenberg, N. and Lawrence Jr., J.C. (1994) Science 266, 653^
656.
[21] Mader, S., Lee, H., Pause, A. and Sonenberg, N. (1995) Mol.
Cell. Biol. 15, 4990^4997.
[22] Lawrence, J.C., Jr., Lin, T.-A., Kong, X., Haystead, T.A.J. and
Hu, C. (1995) in: Diabetes 1994 (Baba, S. and Kaneko, T., Eds.),
pp. 622^629, Elsevier, Amsterdam.
[23] Haystead, T.A.J., Haystead, C.M.M., Hu, C., Lin, T.-A. and
Lawrence Jr., J.C. (1994) J. Biol. Chem. 269, 23185^23191.
[24] Sonenberg, N. (1996) in: Translational Control (Hershey, J.W.B.,
Mathews, M.B. and Sonenberg, N., Eds.), pp. 245^249, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
[25] Diggle, T.A., Moule, S.K., Avison, M.B., Flynn, A., Foulstone,
E.J., Proud, C.G. and Denton, R.M. (1996) Biochem. J. 316,
447^453.
FEBS 22216 18-6-99
D. Yang et al./FEBS Letters 453 (1999) 387^390390
